EUCTR2016-002293-12-ES进行中（未招募）1 期
Phase 2 study of the combination of ibrutinib plus venetoclax in subjects with treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria.
- •2. Active disease meeting at least 1 of the following IWCLL criteria for requiring treatment:
- •- Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia
- •-Massive, progressive, or symptomatic splenomegaly
- •-Massive nodes or progressive or symptomatic lymphadenopathy
- •-Progressive lymphocytosis
- •-Constitutional symptoms
- •3. Measurable nodal disease by computed tomography (CT).
- •4. Adequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to screening, with the exception of pegylated G-CSF (pegfilgrastim) and darbopoeitin which require at least 14 days prior to screening defined as:
- •- Absolute neutrophil count (ANC) >750 cells/µL (750 cells/mm3 or 0.75 x 109/L)
- •- Platelet count >30,000/µL (30,000 cells/mm3 or 30 x 109/L)
- •- Hemoglobin >8.0 g/dL
- •5. Adequate hepatic and renal function defined as:
- •- Serum aspartate transaminase (AST) or alanine transaminase (ALT) =3.0 x upper limit of normal (ULN)
- •-Estimated Creatinine Clearance (CrCl) =60 mL/min (Cockcroft- Gault)
- •- Bilirubin =1.5 x ULN (unless bilirubin rise is due to Gilbert’s syndrome or of non-hepatic origin)
- •6. Prothrombin time (PT)/International normal ratio (INR) <1.5 x (upper limit of notmal) ULN and PTT (activated partial thromboplastin time [aPTT]) <1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder).
- •7. Men and women =18 and <70 years of age.
- •8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •9. Female subjects who are of non-reproductive potential (ie, post-menopausal by history - no menses for =1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Female subjects of reproductive potential must have a negative serum pregnancy test upon study entry.
- •10. Male and female subjects of reproductive potential who agree to use both a highly effective method of birth control (eg, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence2, or sterilized partner) and a barrier method (eg, condom, cervical ring, sponge, etc) during the period of therapy and for 30 days for females and 90 days for males after the last dose of study drug. Male subjects must agree to refrain from sperm donation until 90 days after the last dose of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1. Any prior therapy (including but not limited to chemotherapy, targeted therapy, immunomodulating therapy, radiotherapy, and/or monoclonal antibody) used for treatment of CLL or SLL.
- •2. History of other malignancies, except:
- •- Malignancy treated with curative intent and with no known active disease present for =3 before the first dose of study drug and felt to be at low risk for recurrence by the treating physician
- •-Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •- Adequately treated carcinoma in situ without evidence of disease
- •3. Known or suspected history of Richter’s transformation.
- •4. Concurrent administration of >20 mg/day of prednisone within 7 days of initiation of study drug unless indicated for prophylaxis or management of allergic reactions (eg, contrast).
- •5. Known hypersensitivity to one or more study drugs.
- •6. Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for TLS.
- •7. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
- •8. Recent infection requiring systemic treatment that is ongoing or was completed =14 days before the first dose of study drug, or any uncontrolled active systemic infection.
- •9. Known bleeding disorders (eg, von Willebrand’s disease or hemophilia).
- •10. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
- •11. Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV). Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
- •12. Major surgery within 4 weeks of first dose of study drug.
- •13. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator’s opinion, could compromise the subject’s safety or put the study outcomes at undue risk.
- •14. Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to enrollment.
- •15. Unable to swallow capsules/tablets or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
- •16. Concomitant use of warfarin or other vitamin K antagonists.
- •17. Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor.
- •18. Currently active, clinically significant hepatic impairment Child-Pugh Class B or C according to the Child Pugh classification.
- •19. Lactating or pregnant.
- •20. Unwilling or unable to participate in all required study evaluations and procedures.
- •21. Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations).
研究者
相似试验
进行中（未招募）
1 期
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary TumorsEUCTR2015-003656-40-GBPharmacyclics LLC308
进行中（未招募）
不适用
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary TumorsMetastatic renal cell carcinoma (RCC), advanced urothelial carcinoma, advanced gastric (including gastro-esophageal [GEJ]) adenocarcinoma, and metastatic colorectal adenocarcinoma (CRC)MedDRA version: 18.1Level: PTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10071114Term: Metastatic gastric adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-003656-40-ESPharmacyclics LLC189
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsEUCTR2015-005105-36-CZPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 19.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864EUCTR2015-005105-36-PLPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-005105-36-ITPHARMACYCLICS, INC.74